Interactive Investor is the web's biggest community for discussing UK investments and companies. Compare strategies, share knowledge and validate decisions (or not) on our discussion boards.
Here's Neil Woodford's apology for dire performance
Leading fund manager Neil Woodford has issued an apology and explanation for his recent poor performance.
In a video posted on his website, Woodford said that the performance of CF Woodford Equity Income has been "incredibly painful and [a] difficult thing to have to navigate."
It has been a year to forget for the feted fund manager – with the fund showing a loss of 0.6% over the period – leaving the fund rooted to the bottom of the Investment Association's UK Equity Income fund sector. In contrast, the average fund has returned 8.9% over the past year.
"It's been a difficult period. And I'm very sorry for the poor performance that we've delivered really now since 2016."
However, Woodford remains defiant and stands behind his portfolio: "There's huge potential in the portfolio, huge undervaluation. And it's a great portfolio, one that I own and want to own," he later said.
He noted that, while AstraZeneca's (which accounts for over 8% of Woodford's CF Woodford Equity Income fund) lung cancer drug trial in July was a significant setback for the company, the announcements came alongside "very good results and a number of other very good very positive things". Nevertheless, he adds "that was a sort of an event that the market focused on".
It caused AstraZeneca's share price to plummet from 5,113p (26 July), down to 4,325p (27 July), a decline of 15.4%. The price currently sits at 4,573p.
"It's the biggest position in the portfolios. And of course, that was quite damaging to the funds in terms of the hits," Woodford said.
He also noted the poor performance of Provident Financial, of which Woodford Investment Management owned 19.9%. The doorstep lender saw its share price crash after a number of profit warnings, ultimately leading to it being relegated from the FTSE 100 to the FTSE 250.
Woodford, however, said that while stock specific problems have not helped, he argues underperformance is more down to "the rather odd characteristics of this bull run in the stockmarket".
He adds: "It is a very narrowly led market. The stockmarket seems to want to bid up the prices of stocks that I've talked about before, which provide exposure essentially to Chinese credit growth.
"In very simple terms, the stockmarket has decided that Asia, China is good, the UK is bad. It's a very sort of - it sounds very simple. And maybe it is an oversimplification. But I see that preference playing out in the stockmarket daily."
Echoing previous claims, Woodford said that while "the short-term performance is painful and is difficult…it isn't a permanent loss of capital. And I can and I believe I will rebuild the performance and rebuild that capital that we've lost recently."
This article is for information and discussion purposes only and does not form a recommendation to invest or otherwise. The value of an investment may fall. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser.
Subscribe to Money Observer
Subscribe for just £1 and receive 3 issues
New subscribers can take advantage of this fantastic deal with a money-back guarantee if you decide Money Observer isn't for you.